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Background/Aims:  We investigated the durability of the biochemical and virologic responses after adefovir (ADV) 
discontinuation in lamivudine-resistant (LMV-R) chronic hepatitis B (CHB) patients, and the outcomes of ADV discontinuation 
compared to that of ADV maintenance. Methods: The indication for ADV treatment cessation was an undetectable level of 
hepatitis B virus (HBV) DNA documented on two occasions at least 6 months apart. All patients received additional ADV 
for at least 12 months after the confirmation of undetectable HBV DNA (Cobas TaqMan PCR assay, <70 copies/mL). Of 
36 patients who had a sufficient ADV therapeutic effect, 19 discontinued ADV treatment, while the others maintained it. A 
virologic rebound was arbitrarily defined as the redetection of HBV DNA at a level higher than 10
5 copies/mL. Results: In 
the ADV discontinuation group, ADV treatment and additional therapy were administered for medians of 33 months 
(range, 12-47 months) and 18 months, respectively. The patients were followed for a median of 12 months (range, 
3-30 months) after ADV cessation. During that period, 18 of 19 patients (95%) experienced viral relapse. Viral rebound 
was observed in six patients (32%). However, 12 of 18 patients (67%) exhibited serum HBV DNA levels of less than 
10
5 copies/mL. Biochemical relapses were observed in four of the six patients with viral rebound. In the ADV maintenance 
group, patients were treated for a median of 53 months (range, 31-85 months), and 9 patients (53%) experienced viral 
breakthrough. Conclusions: During short-term follow-up after ADV discontinuation, most patients (95%) exhibited viral 
relapse, whereas and viral breakthrough occurred in about half of patients (53%) maintained on ADV therapy. Therefore, 
the durability of virologic response after ADV discontinuation in LMV-R patients was unsatisfactory. In addition, and viral 
breakthrough was not infrequent in the ADV continuation group. (Korean J Hepatol 2011;17:261-267)
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INTRODUCTION
Adefovir dipivoxil (ADV) is an antiviral agent that is 
effective against wild-type hepatitis B virus (HBV) as well 
as lamivudine-resistant (LMV-R) HBV. Large-scale clinical 
research in treatment-naïve chronic hepatitis B (CHB) 
patients has shown ADV to be effective from biochemical, 
virological, and histological perspectives.
1-3 After treatment 
with ADV, durability is rarely reported. However, in some 
patients, HBeAg seroconversion is reportedly sustained 1 
year after ADV therapy,
4 and among HBeAg-negative CHB 
patients who had had 5 years of effective ADV therapy that 
was then discontinued, 66% had a sustained biochemical 
and virological response.
5
Several authors have observed biochemical and virological 
benefits in LMV-R CHB patients treated with ADV either 
alone or added to ongoing lamivudine therapy.
6-8 A recent 
report showed that a virological response was achieved in 262  The Korean Journal of Hepatology Vol. 17. No. 4, December 2011
55% of patients treated with adefovir and that a biochemical 
response was achieved in 83%.
9 However, whether the viral 
response is sustained after ADV discontinuation in LMV-R 
CHB patients receiving ADV is unknown. In this study, we 
investigated the durability of the biochemical and virological 
responses after discontinuation of ADV in LMV-R CHB 
patients, and compared the responses in patients who 
discontinued ADV with patients who continued ADV. 
PATIENTS AND METHODS
Patients
A total of 120 patients were treated with ADV monotherapy 
for lamivudine resistance. LMV-R CHB was defined as viral 
breakthrough or genotypic resistance of lamivudine.
2  We 
retrospectively analyzed their virologic and biochemical 
responses. Among them, 36 patients showed a virological 
response, and subsequently discontinued ADV. We then 
established consistent criteria as follows: the enrollment 
criterion for HBeAg-positive patients was confirmed HBeAg 
seroconversion with undetectable levels of HBV DNA 
documented on two separate occasions at least 6 months 
apart, while the criterion for HBeAg-negative patients was 
undetectable HBV DNA, documented on two separate 
occasions at least 6 months apart. All patients received 
additional ADV for at least 12 months after confirmation 
of undetectable levels of HBV DNA according to the 
Asian-Pacific consensus statement on the management of 
CHB.
10 Nineteen patients who satisfied the criteria were 
enrolled as ADV discontinvation group and followed for 
more than 3 months after ADV discontinuation. Seventeen 
patients who also satisfied the criteria continued ADV 
monotherapy.
Methods
A liver biochemical test, quantitative HBV DNA, HBeAg, 
and anti-HBe tests were carried out upon discontinuation of 
ADV. Furthermore, these tests were repeated every 3 months 
afterwards, and the therapeutic effect of ADV was examined 
during this follow-up period. Serum HBV DNA was 
measured using the TaqMan polymerase chain reaction 
assay (COBAS TaqMan, Roche Molecular Systems; low 
detection limit was less than 70 copies/mL), and HBeAg and 
anti-HBe were measured using a radioimmunoassay kit 
(HBeAg/Ab IRMA kit, Beijing North Institute of Biological 
Technology). Genotypic resistance was analyzed in some 
patients with suspected LMV-R CHB and performed using 
the restriction fragment mass polymorphism method 
(Green Cross Reference Lab., Yongin, Korea) as previously 
described.
11
Definitions
“Viral relapse” was defined as HBV DNA detection by 
the PCR method after achieving undetectability of HBV 
DNA, and “viral rebound” was defined as HBV DNA 
detection at more than 10
5 copies/mL during the follow-up 
period after ADV discontinuation. “Viral breakthrough” was 
defined as a greater than or equal to 1 log10 increase in the 
serum HBV DNA level from nadir on two consecutive 
occasions after an initial virological response.
2 “Decom-
pensation” was defined as the development of ascites, 
jaundice, bleeding varices, or hepatic encephalopathy. 
“Biochemical relapse” was defined as an elevated alanine 
aminotransferase (ALT) value above the upper normal limit 
after achieving ALT normalization, and “liver cirrhosis” was 
based on histological or ultrasonographic findings of a 
blunted, nodular liver surface accompanied by splenomegaly 
(>10 cm) with a low platelet count (<100,000/mm
3). 
Statistical analysis
For categorical variables, differences between groups 
were calculated using Fisher’s exact test. For continuous 
variables, differences were calculated by the t-test. Logistic 
regression analysis was used to derive the odds ratio and 
95% confidence interval (CI) for the viral rebound’s 
influence on HBV DNA of >10
4 copies/mL. The cumulative 
probability of ADV-resistant mutations was estimated by 
Kaplan-Meyer analysis. A p-value of less than 0.05 was 
considered to indicate statistical significance. All analyses 
were performed using the SPSS software (ver. 12.0 for 
Windows; SPSS, Inc., Chicago, IL, USA).
RESULTS
Baseline characteristics
Baseline characteristics of the 36 patients are summarized 
according to ADV continuation or discontinuation in Table 
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Table 1. Baseline characteristics
Characteristics 
ADV discontinuation
(n=19)
ADV continuation
(n=17)
P-value
Before ADV treatment
  Age (years) 37±10.4 47±11.2 0.353
*
  Sex (Male/Female) 12/7 15/2 0.128
†
  HBeAg (+/-) 10/9 7/10 0.525
†
  ALT (IU/L) 394±99 310±80 0.646
*
  HBV DNA level (log10copies/mL) 7.8±1.0 6.7±1.2 0.005
*
  Liver cirrhosis (+/-) 4/15 3/14 0.797
†
  LMV-Tx. duration (months) 34 (12-72) 18 (9-66) 0.221
*
During ADV treatment
  Additional ADV-Tx. in HBeAg (+) after HBV DNA (-) (months) 18 (16-31) 50 (12-60) 0.001
*
  Additional ADV-Tx. in HBeAg (-) after HBV DNA (-) (months) 18 (12-30) 31 (7-65) 0.001
*
  Total ADV-Tx. duration after LMV-R (months) 33 (12-47) 53 (31-85) 0.001
*
Values are expressed by number, mean±SD, and median (range).
*t-test, 
†Fisher’s exact probability test.
LMV-Tx., lamivudine treatment; ADV-Tx., adefovir treatment; LMV-R, lamivudine-resistance.
Table 2. Durability of virologic and biochemical responses according to HBeAg positivity after discontinuation of ADV treatment 
during the follow-up period
Factors
HBeAg (+) 
n=10
HBeAg (-) 
n=9
Total 
n=19
Viral relapse 9 (90%) 9 (100%) 18 (95%)
Viral rebound 3 (30%) 3 (33%) 6 (32%)
HBeAg reversion 1 (10%) 0 1 (5%)
ALT elevation (>1×UNL) 2 (20%) 2 (22%) 4 (21%)
ALT flare (>10×UNL) 1 (10%) 0 1 (5%)
Re-treatment 2 (20%) 1 (11%) 3 (16%)
“Viral relapse” was defined as HBV DNA detection by PCR after failure to detect HBV DNA (Cobas TaqMan DNA PCR, detection 
limit: < 70 copies/mL); “Viral rebound” as HBV DNA detection at more than 10
5 copies/mL; and “HBeAg reversion” as the positivity 
of HBeAg after HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients.
ADV, adefovir dipivoxil; HBeAg, hepatitis B e antigen; ALT, alanine aminotransferase.
mean age of enrolled patients was 37 (SD±10.4) years, and 
four of them showed compensated liver cirrhosis with a 
Child-Pugh score of 5. In ADV continuation group, the 
mean age was 47 (SD±11.2), and 3 patients had compensated 
liver cirrhosis. In ADV continuation group baseline HBV 
DNA level was lower compared with that in ADV 
discontinuation group (P=0.005). However, other factors 
showed no difference between two groups before ADV 
treatment. During ADV treatment, ADV continuation group 
showed more longer treatment period than ADV discontinuation 
group (P=0.001).
In ADV discontinuation group, ten patients were HBeAg 
positive, and the mean serum ALT and HBV DNA levels 
were, respectively, 394 (SD±99) IU/L and 8.3 (SD±0.2) 
log10 copies/mL before ADV treatment. The patients were 
treated with ADV for a median of 33 (range, 12-47) months, 
and after the treatment, additional therapy was administered 
for a median of 18 months. In ADV continuation group, they 
continuously received ADV monotherapy for a median of 53 
months (range, 31-85).264  The Korean Journal of Hepatology Vol. 17. No. 4, December 2011
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Figure 1. Graph showing changes in HBV DNA levels during 
the follow-up period after ADV discontinuation. The thick solid 
lines illustrate the change in the HBV DNA level of patients 
with viral rebound, and the thin solid lines illustrate viral relapse 
without viral rebound. Viral rebound was defined as HBV DNA 
being detected at more than 10
5 copies/mL during the follow-up 
period after ADV discontinuation. The dotted line indicates 5 
log
10 copies/mL. Viral rebound (VR) was defined as HBV DNA 
detection at more than 10
5
  copies/mL during the follow-up period
after ADV discontinuation.
Durability of virological and biochemical 
response after ADV discontinuation.
During the follow-up period after ADV treatment, 18 of 
the 19 patients (95%) experienced viral relapse after ADV 
discontinuation. In addition, six of the 18 patients (33%) 
showed viral rebound as previously defined and their serum 
HBV DNA levels continued to increase with time and 
accompanied by ALT elevation. One patient in the viral 
rebound group experienced HBeAg reversion, but decom-
pensation was not observed. Patients who experienced 
biochemical relapse were retreated with antiviral agents. 
Three patients were retreated with ADV monotherapy because 
they showed a good response (Table 2). The virologic and 
biochemical responses after ADV discontinuation were not 
significantly different between HBeAg positive and negative 
patients.
Fluctuation of HBV DNA levels during follow-up 
period after ADV discontinuation
The change in the HBV DNA level for each patient after 
ADV discontinuation is shown in Figure 1. All except 
one patient experienced viral relapse at 3 months after 
discontinuation. The numbers of patients in accordance with 
HBV DNA levels of relapse at 3 months were as follows: 
four at >10
5 copies/mL, four from 10
5 to 10
4 copies/mL, 10 
at <10
4 copies/mL, and one below the detection limit. 
Although HBV DNA levels showed fluctuation during the 
follow-up period, the numbers of patients in accordance 
with HBV DNA levels of relapse at 12 months of disconti-
nuation or at the endpoint of follow-up were as follows: four 
at > 10
5 copies/mL, three from 10
5 to 10
4 copies/mL, 11 at 
<10
4 copies/mL, and one below the detection limit. Viral 
rebound was observed in six patients (33%), but the 
remaining 12 (67%) showed a serum HBV DNA level of 
less than 10
5 copies/mL. In the viral rebound group, some 
showed biochemical relapses, HBeAg reversion, and even 
ALT flare-up.
Risk factors for viral rebound after ADV 
discontinuation
We analyzed various factors for a possible association 
with viral rebound, including age, sex, ALT level, cirrhosis, 
baseline HBV DNA level, viral response to ADV treatment, 
and the additional duration of ADV treatment. The only 
factor significantly associated with viral rebound was an 
HBV DNA level of more than 10
4 copies/mL 3 months 
after ADV discontinuation (Table 3). Additionally, logistic 
regression analysis was used to identify influence of each 
factor on viral rebound. An HBV DNA level of more than 
10
4 copies/mL 3 months after ADV discontinuation showed 
a significant influence (odds ratio, 13.333; 95% CI, 
1.048-169.557; P=0.046).
Viral breakthrough in ADV continuation group
We analyzed viral breakthrough in ADV continuation 
group. Viral breakthrough was observed after 38 months in 
ADV continuation group. They received ADV monotherapy 
for a median of 53 months (range, 31-85). During ADV 
treatment 9 patients (53%) experienced a viral breakthrough. 
The patients experiencing a viral breakthrough did not show 
decompensation and all of them received rescue therapy 
with entecavir.
DISCUSSION
It is not clear when to stop nucleoside/nucleotide analogue 
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Table 3. Risk factors related to virologic and biochemical responses according to viral rebound
Factors
Viral rebound (+)
n=6
Viral rebound (-)
n=13
P-value
Age (years) 32±4 41±9 0.123
*
Sex (Male/Female) 5/1 7/6 0.325
†
Associated with ADV treatment
  ALT (IU/L) 264±254 351±322 0.895
*
  Bilirubin (mg/dL) 2.2±2.6 2.2±2.8 0.967
*
  Albumin (mg/dL) 4.4±0.4 4.3±0.3 0.395
*
  Liver cirrhosis (Y/N) 1/5 3/10 0.657
†
  HBeAg (+ve/-ve) 3/3 7/6 0.987
†
  HBV DNA level (log10  copies/mL) 7.5 8.1 0.190
*
  Undetactable of HBV DNA at 6 months 3/3 6/7 0.876
†
  Undetactable of HBV DNA at 12 months 5/1 9/4 0.516
*
  Duration LMV Tx. 32 (27-72) 36 (19-55) 0.341
†
  Duration ADV Tx. 26 (26-36) 30 (28-42) 0.908
†
  Duration of additional ADV Tx. 13 (12-31) 16 (12-25) 0.276
†
Associated with ADV discontinuation
  HBV DNA > 10
4 cps/mL at off-Tx. 3 months 5/1 3/10 0.047
*
Values are expressed by number, means±SD, and median (range). 
*t-test, 
†Fisher’s exact probability test.
ALT, alanine aminotransferase at baseline of adefovir treatment; LMV Tx., lamivudine treatment; ADV Tx., adefovir treatment; off-Tx., 
discontinuation of treatment.
discontinued after HBsAg loss during NA treatment in 
HBeAg-positive and -negative patients.
12 In an HBsAg loss 
state, HBV DNA is not detectable in serum or is detectable 
only at low levels in liver. This state is associated with an 
improvement in outcomes, including a reduced risk of 
cirrhosis and hepatocellular carcinoma (HCC).
13 However, 
HBsAg loss is rarely experienced during NA treatment.
14,15 
In many countries, the current practice guidelines for 
treatment end points suggest that treatment can be 
discontinued after seroconversion to anti-HBe, achievement 
of a decline in HBV DNA to non-detection by PCR, and a 
return of ALT to normal levels. If needed, additional therapy 
of more than 6 to 12 months can be considered.
2,10,12 In the 
present study, we applied “strict” enrollment criteria: ALT 
normalization and undetectable HBV DNA by PCR, 
sufficient additional therapy (more than 12 months), and, in 
HBeAg-positive CHB patients, HBeAg seroconversion.
10
Several studies on the durability of LMV in CHB patients 
have been reported. A Western study showed a 2-year 
cumulative rate of recurrence of approximately 50%.
16 An 
Asian study reported that 49.2% of CHB patients with HBeAg 
seroconversion and short additional therapy experienced 
recurrence, and risk factors were the pretreatment HBV 
DNA level and the period of additional therapy.
17 However, 
few data are available concerning the durability of ADV in 
treatment-naïve CHB patients. One study reported that 90% 
of 76 patients had sustained HBeAg seroconversion 1 year 
after ADV discontinuation.
18 Additionally, a sustained 
response rate following the discontinuation of ADV after 4 
or 5 years of effective ADV treatment has been reported in 
up to 66% of ADV treatment-naïve patients. However, 
whether the viral response is sustained after ADV disconti-
nuation in LMV-R CHB patients receiving ADV is 
unknown.
5
The aim of this study was to investigate the durability of 
the virological and biochemical responses after ADV 
discontinuation in LMV-R patients, to analyze the factors 
associated with viral rebound, and to find out the benefit of 
ADV discontinuation compared to ADV continuation 
treatment. During the follow-up period (a median of 11 266  The Korean Journal of Hepatology Vol. 17. No. 4, December 2011
months) in ADV discontinuation, almost all patients showed 
viral relapse; that is, they showed detectable levels of HBV 
DNA by PCR. During the followup period, 12 patients 
(67%) showed a low serum HBV DNA level (fewer than 
10
5  copies/mL), and biochemical relapses were observed 
four patients (21%). These results are similar to those of an 
earlier report on ADV treatment-naïve CHB patients.
5
The mechanism by which a high HBV DNA level causes 
the progression of liver disease is not fully understood. The 
role of HBV DNA level was recently reported in a natural 
history study. The REVEAL study showed that a baseline 
level of HBV DNA of >100,000 copies/mL was a strong 
predictor for HCC development compared with a baseline 
level of <100,000 copies/mL.
19 Zacharakis et al showed in a 
prospective cohort study showed that an HBV DNA level 
of >10,000 copies/mL and a normal ALT at baseline and at 
follow-up were independent predictors
20 for liver disease 
progression in inactive carrier state patients. In other studies, 
after HBeAg seroconversion, most patients showed sustained 
normal serum ALT, low serum HBV DNA (fewer than 10
5 
copies/mL), and minimal histological changes.
21-23  In the 
present study, although we used “strict” discontinuation 
criteria, 63% showed sustained normal ALT and low HBV 
DNA levels (less than 10
5 copies/mL) during the follow-up 
period. 
As for continuation of the ADV treatment, our study did 
not show a satisfactory result in ADV continuation group 
although the patient number is small. During a median of 53 
months (range, 31-85), totally 9 patients (53%) experienced 
a viral breakthrough. Although the randomized prospective 
study, 17 patients enrolled in ADV continuation group 
showed a good initial response to ADV treatment, but about 
half of them finally experienced viral breakthrough. Thus, 
the decision as to when to stop HBV treatment needs further 
consideration.
In past studies of other NA treatments, the durability of 
and response to NA treatment were associated with the 
pretreatment HBV DNA level and ALT value, age, and 
additional treatment period.
17,24,25 In our study, we analyzed 
multiple factors, including the above factors, but the only 
factor associated with viral rebound and biochemical relapse 
was an HBV-DNA level of more than 10
4 copies/mL 
3 months after ADV discontinuation. We believe that this 
shows that close follow-up is very important in the early 
period after NA discontinuation, and we assume that we did 
not find other risk factors associated with relapse because 
we analyzed such a small number of patients.
Our study has some limitations because of its retrospective 
nature, although we used strict enrollment criteria according 
to APASL guidelines. First, the sample size was small, and 
because patients were enrolled by data selection, selection 
bias was present. Second, genotype mutation analysis of 
lamivudine was not performed in some patients, so we could 
not investigate risk factors according to the genotype 
mutation pattern. Third, ADV monotherapy in LMV-R CHB 
patients is no longer recommended according to the current 
guidelines, so the results of this study will not affect the 
decision of the current treatment direction. However, despite 
these limitations, this study offers a current guideline regarding 
the discontinuation of antiviral agents when they are not 
very effective and when longer treatment duration may be 
needed in LMV-R CHB patients.
In conclusion, during a short-term follow-up of ADV 
discontinuation, most patients showed viral relapse; approxi-
mately two-thirds of patients with viral relapse maintained a 
normal ALT level and an HBV-DNA level of fewer than 10
5 
copies/mL, and one-third of patients experienced viral 
rebound and re-treatment with antiviral agents. In ADV 
maintenance about half of patients (53%) showed viral 
breakthrough. Therefore, antiviral response was not durable 
after ADV discontinuation in LMV-R patients was unsatis-
factory, and the benefit was modest compared to ADV 
maintenance. In LMV-R patients, antiviral treatment with 
more potent drugs and longer duration is recommended.
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